166 related articles for article (PubMed ID: 34850772)
1. Efficacy and safety of sintilimab-based regimens against advanced gastric and gastroesophageal junction adenocarcinoma.
Wang Y; Zhao J; Yu H; Wang J; Zhang N; Cao B
J Cancer Res Ther; 2021 Nov; 17(5):1234-1240. PubMed ID: 34850772
[TBL] [Abstract][Full Text] [Related]
2. Safety and efficacy of sintilimab combined with oxaliplatin/capecitabine as first-line treatment in patients with locally advanced or metastatic gastric/gastroesophageal junction adenocarcinoma in a phase Ib clinical trial.
Jiang H; Zheng Y; Qian J; Mao C; Xu X; Li N; Xiao C; Wang H; Teng L; Zhou H; Wang S; Zhu D; Peng B; Shen L; Xu N
BMC Cancer; 2020 Aug; 20(1):760. PubMed ID: 32795349
[TBL] [Abstract][Full Text] [Related]
3. Initial Report of Second-Line FOLFIRI in Combination with Ramucirumab in Advanced Gastroesophageal Adenocarcinomas: A Multi-Institutional Retrospective Analysis.
Klempner SJ; Maron SB; Chase L; Lomnicki S; Wainberg ZA; Catenacci DVT
Oncologist; 2019 Apr; 24(4):475-482. PubMed ID: 30470690
[TBL] [Abstract][Full Text] [Related]
4. Sintilimab Plus Chemotherapy for Unresectable Gastric or Gastroesophageal Junction Cancer: The ORIENT-16 Randomized Clinical Trial.
Xu J; Jiang H; Pan Y; Gu K; Cang S; Han L; Shu Y; Li J; Zhao J; Pan H; Luo S; Qin Y; Guo Q; Bai Y; Ling Y; Yang J; Yan Z; Yang L; Tang Y; He Y; Zhang L; Liang X; Niu Z; Zhang J; Mao Y; Guo Y; Peng B; Li Z; Liu Y; Wang Y; Zhou H;
JAMA; 2023 Dec; 330(21):2064-2074. PubMed ID: 38051328
[TBL] [Abstract][Full Text] [Related]
5. Tislelizumab Plus Chemotherapy as First-line Treatment for Advanced Esophageal Squamous Cell Carcinoma and Gastric/Gastroesophageal Junction Adenocarcinoma.
Xu J; Bai Y; Xu N; Li E; Wang B; Wang J; Li X; Wang X; Yuan X
Clin Cancer Res; 2020 Sep; 26(17):4542-4550. PubMed ID: 32561664
[TBL] [Abstract][Full Text] [Related]
6. FDA Approval Summary: Pembrolizumab for Recurrent Locally Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Expressing PD-L1.
Fashoyin-Aje L; Donoghue M; Chen H; He K; Veeraraghavan J; Goldberg KB; Keegan P; McKee AE; Pazdur R
Oncologist; 2019 Jan; 24(1):103-109. PubMed ID: 30120163
[TBL] [Abstract][Full Text] [Related]
7. Pembrolizumab alone or in combination with chemotherapy as first-line therapy for patients with advanced gastric or gastroesophageal junction adenocarcinoma: results from the phase II nonrandomized KEYNOTE-059 study.
Bang YJ; Kang YK; Catenacci DV; Muro K; Fuchs CS; Geva R; Hara H; Golan T; Garrido M; Jalal SI; Borg C; Doi T; Yoon HH; Savage MJ; Wang J; Dalal RP; Shah S; Wainberg ZA; Chung HC
Gastric Cancer; 2019 Jul; 22(4):828-837. PubMed ID: 30911859
[TBL] [Abstract][Full Text] [Related]
8. Real-World Effectiveness and Safety of Ramucirumab as a Second-Line Treatment for Patients with Unresectable Advanced or Metastatic Gastric/Gastroesophageal Junction Adenocarcinoma in Japan and South Korea: A Systematic Literature Review.
Zhang X; Zhou L; Zhou C; Shen L
Adv Ther; 2024 Jun; 41(6):2112-2132. PubMed ID: 38619719
[TBL] [Abstract][Full Text] [Related]
9. [Enhancing survival outcomes in stage Ⅲ gastric/esophagogastric junction cancer: a retrospective study of immune checkpoint inhibitors and adjuvant chemotherapy based on real-world data].
Yang XQ; Rao Z; Wei HK; Xue ZC; Liu HY; Duan QF; Sun XW; Wang W
Zhonghua Wei Chang Wai Ke Za Zhi; 2024 Apr; 27(4):395-402. PubMed ID: 38644245
[No Abstract] [Full Text] [Related]
10. Phase II study of cetuximab in combination with FOLFIRI in patients with untreated advanced gastric or gastroesophageal junction adenocarcinoma (FOLCETUX study).
Pinto C; Di Fabio F; Siena S; Cascinu S; Rojas Llimpe FL; Ceccarelli C; Mutri V; Giannetta L; Giaquinta S; Funaioli C; Berardi R; Longobardi C; Piana E; Martoni AA
Ann Oncol; 2007 Mar; 18(3):510-7. PubMed ID: 17164226
[TBL] [Abstract][Full Text] [Related]
11. A Randomized Phase II Study of FOLFOX With or Without the MET Inhibitor Onartuzumab in Advanced Adenocarcinoma of the Stomach and Gastroesophageal Junction.
Shah MA; Cho JY; Tan IB; Tebbutt NC; Yen CJ; Kang A; Shames DS; Bu L; Kang YK
Oncologist; 2016 Sep; 21(9):1085-90. PubMed ID: 27401892
[TBL] [Abstract][Full Text] [Related]
12. Prognostic and predictive value of mismatch repair deficiency in gastric and gastroesophageal junction adenocarcinoma patients receiving neoadjuvant or adjuvant chemotherapy.
Li Z; Wang Y; Ying X; Zhang L; Gao X; Jia Y; Zhang L; Wu A; Su X; Ji J
J Surg Oncol; 2021 Dec; 124(8):1356-1364. PubMed ID: 34515995
[TBL] [Abstract][Full Text] [Related]
13. CabaGast: multicentre, Phase II study with cabazitaxel in previously treated patients with advanced or metastatic adenocarcinoma of the esophagogastric junction and stomach.
Schmalenberg H; Al-Batran SE; Pauligk C; Zander T; Reichart A; Lindig U; Kleiß M; Müller L; Bolling C; Seufferlein T; Reichardt P; Kullmann F; Eschenburg H; Schmittel A; Egger M; Block A; Goetze TO
J Cancer Res Clin Oncol; 2018 Mar; 144(3):559-569. PubMed ID: 29285668
[TBL] [Abstract][Full Text] [Related]
14. Phase 1 trial of avelumab (anti-PD-L1) in Japanese patients with advanced solid tumors, including dose expansion in patients with gastric or gastroesophageal junction cancer: the JAVELIN Solid Tumor JPN trial.
Doi T; Iwasa S; Muro K; Satoh T; Hironaka S; Esaki T; Nishina T; Hara H; Machida N; Komatsu Y; Shimada Y; Otsu S; Shimizu S; Watanabe M
Gastric Cancer; 2019 Jul; 22(4):817-827. PubMed ID: 30515672
[TBL] [Abstract][Full Text] [Related]
15. Andecaliximab/GS-5745 Alone and Combined with mFOLFOX6 in Advanced Gastric and Gastroesophageal Junction Adenocarcinoma: Results from a Phase I Study.
Shah MA; Starodub A; Sharma S; Berlin J; Patel M; Wainberg ZA; Chaves J; Gordon M; Windsor K; Brachmann CB; Huang X; Vosganian G; Maltzman JD; Smith V; Silverman JA; Lenz HJ; Bendell JC
Clin Cancer Res; 2018 Aug; 24(16):3829-3837. PubMed ID: 29691300
[No Abstract] [Full Text] [Related]
16. Subgroup analyses of the safety and efficacy of ramucirumab in Japanese and Western patients in RAINBOW: a randomized clinical trial in second-line treatment of gastric cancer.
Shitara K; Muro K; Shimada Y; Hironaka S; Sugimoto N; Komatsu Y; Nishina T; Yamaguchi K; Segawa Y; Omuro Y; Tamura T; Doi T; Yukisawa S; Yasui H; Nagashima F; Gotoh M; Esaki T; Emig M; Chandrawansa K; Liepa AM; Wilke H; Ichimiya Y; Ohtsu A
Gastric Cancer; 2016 Jul; 19(3):927-38. PubMed ID: 26510663
[TBL] [Abstract][Full Text] [Related]
17. Safety and Efficacy of Pembrolizumab Monotherapy in Patients With Previously Treated Advanced Gastric and Gastroesophageal Junction Cancer: Phase 2 Clinical KEYNOTE-059 Trial.
Fuchs CS; Doi T; Jang RW; Muro K; Satoh T; Machado M; Sun W; Jalal SI; Shah MA; Metges JP; Garrido M; Golan T; Mandala M; Wainberg ZA; Catenacci DV; Ohtsu A; Shitara K; Geva R; Bleeker J; Ko AH; Ku G; Philip P; Enzinger PC; Bang YJ; Levitan D; Wang J; Rosales M; Dalal RP; Yoon HH
JAMA Oncol; 2018 May; 4(5):e180013. PubMed ID: 29543932
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety for Apatinib treatment in advanced gastric cancer: a real world study.
Zhang Y; Han C; Li J; Zhang L; Wang L; Ye S; Hu Y; Bai L
Sci Rep; 2017 Oct; 7(1):13208. PubMed ID: 29038432
[TBL] [Abstract][Full Text] [Related]
19. HX008, an anti-PD1 antibody, plus irinotecan as second-line treatment for advanced gastric or gastroesophageal junction cancer: a multicenter, single-arm phase II trial.
Song Y; Li N; Li Q; Liang X; Zhang S; Fan Q; Yin X; Zhuang Z; Liu Y; Zhang J; Kou X; Zhong H; Wang X; Dou Y; Huang J
J Immunother Cancer; 2020 Oct; 8(2):. PubMed ID: 33060149
[TBL] [Abstract][Full Text] [Related]
20. Safety and efficacy of pembrolizumab in combination with S-1 plus oxaliplatin as a first-line treatment in patients with advanced gastric/gastroesophageal junction cancer: Cohort 1 data from the KEYNOTE-659 phase IIb study.
Kawazoe A; Yamaguchi K; Yasui H; Negoro Y; Azuma M; Amagai K; Hara H; Baba H; Tsuda M; Hosaka H; Kawakami H; Oshima T; Omuro Y; Machida N; Esaki T; Yoshida K; Nishina T; Komatsu Y; Han SR; Shiratori S; Shitara K
Eur J Cancer; 2020 Apr; 129():97-106. PubMed ID: 32145474
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
